ArticleFood chemistry. Molecular sciences2026
Low-dose l-carnitine supplementation attenuates hepatic lipid accumulation in chow-fed mice: Insights from integrated multi-omics analysis.
Article in Food chemistry. Molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most studies on l-carnitine and hepatic lipid metabolism have focused on deficiency or HFD-associated metabolic disorders, whereas its low-dose nutritional effects under standard chow-fed conditions remain unclear. In this study, standard chow-fed C57BL/6 J mice were orally administered low doses of l-carnitine for 35 days, and hepatic responses were evaluated using phenotypic, histological, metabolomic, transcriptomic, and proteomic analyses. l-carnitine supplementation reduced liver weight and hepatic lipid accumulation in a dose-associated manner, accompanied by decreased hepatocyte area and reduced H&E-based hepatocellular vacuolation. Multi-omics integration suggests attenuation of canonical fatty acid oxidation marker activation. Instead, l-carnitine treatment was associated with attenuation of lipogenesis-related signatures, including reduced xylulose-5-phosphate abundance, decreased PPP2CB protein abundance, and lower Acaca and Fasn levels, providing evidence for a potential suppression of a Xu-5P/PP2A/ChREBP-associated lipogenic signature. Concurrent remodeling of amino acid-, carbohydrate-, pyrimidine-, and ascorbate/aldarate-related pathways further indicated coordinated regulation of substrate metabolism, nucleotide metabolism, and detoxification-associated processes. Together, these findings highlight a previously underexplored nutritional dimension of l-carnitine action, showing that low-dose supplementation can reshape hepatic lipid-associated metabolic networks even under standard chow-fed, non-HFD conditions. This study extends the current understanding of l-carnitine from a classical fatty acid transport cofactor to a dietary factor involved in the network-level regulation of hepatic lipid homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.